Monocyte-Megakaryocyte Interaction

Monocyte-Megakaryocyte Interaction refers to the complex cellular crosstalk between monocytes (and their derivative macrophages) and megakaryocytes within the bone marrow microenvironment. This interaction is mediated by direct cell-cell contact via adhesion molecules such as P-selectin (CD62P) and PSGL-1, as well as paracrine signaling through cytokines like TGF-beta, IL-6, and CXCL12 (PubMed: 28242705). In healthy states, this interaction regulates hematopoiesis and platelet production by maintaining the hematopoietic stem cell niche. However, in pathological conditions like primary myelofibrosis, aberrant interaction leads to excessive cytokine release and fibroblast activation, contributing to bone marrow scarring and ineffective erythropoiesis (PubMed: 30333115). While not a single molecular target, therapeutic strategies often aim to disrupt the signaling pathways (e.g., JAK/STAT) or adhesion molecules that facilitate this interaction to treat myeloproliferative neoplasms. Drugs like ruxolitinib modulate this axis by reducing the inflammatory output of these interacting cells and improving the marrow microenvironment.

Other names

Megakaryocyte-monocyte crosstalkMegakaryocyte-macrophage interactionMK-monocyte axisMegakaryocyte-monocyte niche interaction

Modulation of the inflammatory and fibrotic signaling pathways (e.g., JAK/STAT, TGF-beta) and adhesion molecules that mediate the crosstalk between megakaryocytes and monocytes in the bone marrow microenvironment.